Panelists discuss the future of Bruton tyrosine kinase (BTK) inhibitor therapies, considering emerging treatments, regulatory changes, evolving cost dynamics, and the current unmet needs in chronic ...

More information: Marc Nazaré, Development of selective inhibitors of phosphatidylinositol 3-kinase C2α, Nature Chemical Biology (2022). DOI: 10.1038/s41589-022-01118-z Journal information ...

In a Phase I/II clinical trial, TKI-pretreated NSCLC patients given zidesamtinib had an overall response rate of 44 percent.

The promiscuity of most kinase inhibitors can cause drug toxicity and complicate the interpretation of experiments. Rather than assessing kinase-compound binding, Anastassiadis et al. use ...

Avistone Announces Preclinical Results for ANS014004, a Type II c-Met Tyrosine Kinase Inhibitor (TKI) at the AACR-NCI-EORTC International Conference ...

Switching to a second-line Janus kinase (JAK) inhibitor resulted in steroid-free clinical remission in about half of the patients with active ulcerative colitis (UC) after induction; compared with ...

Tyrosine kinase inhibitors, such as gefitinib (Iressa ™, ZD1839), block the EGFR. As a result, there is inhibition of cellular proliferation, promotion of apoptosis, and inhibition of anti ...

Covalent (irreversible) Bruton’s tyrosine kinase (BTK) inhibitors have transformed the treatment of multiple B-cell cancers, especially chronic lymphocytic leukemia (CLL). However, resistance ...

NVL-655 is a novel brain-penetrant ALK-selective inhibitor designed to treat tumors that have developed resistance to first-, second-, and third-generation ALK inhibitors, including tumors with ...